Forward Industries, Inc. — FY2015 Form 10-K
Reporting period: Fiscal year ended September 30, 2015. This is an annual filing, not a standalone fourth-quarter report.
Business context
Forward designs and distributes customized carrying and protective solutions for OEMs; it outsources substantially all production to suppliers in China. Diabetic-monitoring products generated 83% of FY2015 sales. The company had exited its retail business, which is reported as discontinued operations.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Net sales | $30.0 million | $33.4 million |
| Gross profit / gross margin | $5.8 million / 19% | $6.6 million / 20% |
| Operating loss | $1.5 million | $0.1 million |
| Loss from continuing operations | $1.6 million | $0.5 million |
| Net loss | $1.4 million | $0.8 million |
| Net loss applicable to common equity | $1.9 million | $1.0 million |
| Net cash used in operating activities | $2.0 million | Net cash provided of $0.2 million |
| Cash and cash equivalents at year-end | $4.0 million | $6.5 million |
- Sales fell 10%; gross profit decreased 12%. The reported gross margin declined about one percentage point.
- Sales and marketing expense decreased 16% to $2.4 million, while general and administrative expense rose 29% to $4.9 million, primarily due to proxy-defense and other legal professional fees and former executive-related costs.
- FY2015 investing cash flow was positive $0.9 million, mainly from liquidating marketable securities. Financing cash outflow was $1.3 million, primarily to redeem all outstanding convertible preferred stock.
- At September 30, 2015, working capital was $7.3 million, the current ratio was 2.4, and the quick ratio was 1.8. The company reported no short- or long-term debt.
Changes, outlook, and risks
- Diabetic-product sales declined $1.5 million, and other-product sales declined $1.9 million. Four customers accounted for 82% of sales, up from 76%; the largest customer contributed 33%.
- Management attributed weaker results to lower sales volumes, legacy diabetic programs nearing the end of their life cycles, customer price pressure, and rising China-based supplier costs. It continued investing in sales, design, and support capacity and began seeking complementary acquisition targets.
- Management said existing liquidity should be adequate for operating and financial needs over the next 12 months, but provided no quantified earnings or revenue guidance. It cautioned that growth investments may not succeed and future profitability is not assured.
- Material risks include customer and product concentration, volatile order volumes, price and margin pressure, foreign-currency exposure, and dependence on a single exclusive sourcing agent and a concentrated supplier base. The CEO is a principal of the sourcing agent; the renewed agreement runs through September 2018 and provides for a $100,000 monthly fee plus 4% of adjusted gross profit.
- Discontinued operations recorded $0.2 million of FY2015 income from a third-party recovery related to a previously reserved G-Form receivable. The company also recorded $0.5 million of preferred-stock dividends and accretion in determining loss applicable to common equity; the preferred shares were redeemed for approximately $1.3 million in February 2015.
- No material legal proceedings were reported as of year-end. Management concluded disclosure controls and internal control over financial reporting were effective; the independent auditor did not attest to internal-control effectiveness.
Investor verification points
- Check subsequent sales, orders, and customer-program developments, especially for the four major diabetic customers and legacy platforms.
- Review customer concentration, payment exposure to contract manufacturers, hub inventory, and working-capital trends.
- Assess the sourcing-agent relationship, related-party fees, supplier concentration, and potential effects of rising costs on gross margins.
- Reconcile the reported net loss with the larger loss applicable to common equity, including preferred-stock accretion and dividends, and confirm the effects of the redemption.
- Monitor cash burn and liquidity after the decline in cash and the preferred-stock redemption; the filing’s 12-month liquidity assessment is management’s expectation, not a guarantee.